CAMBRIDGE, Mass. — The road from lab bench to bedside is littered with failures. Most drug candidates never make it. But Ernexa Therapeutics believes it has something different.
The company announced Tuesday it has finished manufacturing process development for ERNA-101, its lead cell therapy candidate. Production under strict Good Manufacturing Practice standards is now underway.
An Investigational New Drug application is slated for the third quarter of 2026. This puts Ernexa on track to become a clinical-stage company by year-end 2026, when it expects to start a first-in-human Phase 1 study. ERNA-101 targets what oncologists call “immunologically cold” tumors.
These are cancers that the immune system simply does not see. They hide.
They do not provoke an attack. Standard immunotherapies often fail against them. Ernexa’s approach is engineered from the ground up.
The therapy is an allogeneic induced mesenchymal stem cell, or iMSC, derived from induced pluripotent stem cells. That means it comes from a donor cell line, not the patient’s own body. It is designed to be off-the-shelf, ready to use.
The cells are programmed to home in on tumors. Once there, they deliver a proprietary fusion cytokine — a combination of IL-7 and IL-15 — directly into the tumor microenvironment.
The idea is to turn a cold tumor hot, to wake the immune system up from the inside. Sanjeev Luther, Ernexa’s President and CEO, called the current period one of the most important in the company’s history. “With GMP manufacturing underway, technology transfer activities progressing and our IND submission expected in the third quarter of 2026, we believe we are entering one of the most important periods in the Company’s history,” he said.
The company is small. It has no approved products.
It has not yet treated a single patient in a clinical trial. That changes next year — if the FDA allows it. The IND submission is the formal request to begin human testing.
The agency has 30 days to review it. If nothing stops the process, the Phase 1 study will enroll the first patients in late 2026. Autoimmune disease is also in the crosshairs.
The same technology that targets cold tumors may have applications beyond oncology. Ernexa has not detailed those plans, but the press release explicitly names both advanced cancer and autoimmune disease as targets for ERNA-101.
The science behind iMSCs is relatively young. Induced pluripotent stem cells were first created in 2006, a breakthrough that won Shinya Yamanaka a Nobel Prize. Turning those into mesenchymal stem cells — and then engineering them to carry a therapeutic payload — is a multistep process that few companies have mastered.
Ernexa says it has. The completion of manufacturing process development is a concrete milestone.
GMP production is the next hurdle. The company must prove it can make the therapy consistently, safely, and at scale. That is not a given.
Cell therapies are among the most complex drugs ever attempted. They are living medicines. They must survive shipping, storage, and infusion.
They must find the right target and do the right thing once they get there. The cold tumor problem is real.
It is one reason why checkpoint inhibitors like Keytruda work wonders for some patients and do nothing for others. If ERNA-101 can change that, it would be a genuine advance. But first, the IND.
Then the Phase 1 safety data. Then the efficacy signals.
The timeline is aggressive. The science is ambitious. The company is betting that its engineered stem cells can do what nature’s immune system cannot.
